Phoenix Molecular Designs

📍 San Diego, United States🗓 Founded 2012👥 10 employees💰 Last funded May 2018
Biotechnology Research🌐 phoenixmd.ca
Website LinkedIn
Phoenix Molecular Designs is a clinical-stage biotechnology company that is developing small molecule kinase inhibitors as a targeted therapy for cancer. We are focused on treating one of the most aggressive types of breast cancer, Triple Negative Breast Cancer (TNBC), which currently has limited durable options. Our patented cancer compounds position us in the lead to fast track our product to market as it fills an unmet medical need. Our cancer therapy has the potential to save lives and improve quality of life.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in Phoenix Molecular Designs?
Phoenix Molecular Designs has 1 investors on record on gritt.io and 1 late-stage investors.
When did Phoenix Molecular Designs last raise funding?
The most recent investment in Phoenix Molecular Designs recorded on gritt.io was in May 2018.
When was Phoenix Molecular Designs founded?
Phoenix Molecular Designs was founded in 2012.
What industry is Phoenix Molecular Designs in?
Phoenix Molecular Designs operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Phoenix Molecular Designs based?
Phoenix Molecular Designs is headquartered in San Diego, United States.